eScholarship
metadata only
Targeting the insulin-like growth factor-1 receptor in MTAP-deficient renal cell carcinoma
Renal cell carcinoma (RCC) has emerged as a metabolic disease characterized by dysregulated expression of metabolic enzymes. Patients with metastatic RCC have an unusually poor prognosis and near-universal resistance to all current therapies. To improve RCC treatment and the survival rate of patient
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib#1362661
- All screens lead to polo-like kinase 1: A central node in cancer therapeutics and resistance#1345904
- Integrative Profiling of Metabolic CYP Expression, DNA Mutation Rates, and Immune Cell Infiltration for Survival Prognosis in Hepatocellular Carcinoma / Mona Dawood, Axel Guthart, Ednah Ooko, Ralf Weiskirchen, Thomas Efferth, Joelle C. Boulos#628969
- Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling#652785
- Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling.#457464
Record · ID 1298603
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive